The main risk is not technology viability but value capture. Celestica can execute well and still disappoint if
hyperscaler concentration, next-cycle
qualification misses, or underfilled new capacity turn scarce execution into ordinary manufacturing volume. The business is meaningfully better than old
EMS history, but it remains tied to customer allocations,
capex timing and supply-chain continuity.